ARIAD’s most prominent drug discoveries include Iclusig, designed for patients with all forms of Philadelphia chromosome-positive [Ph+] chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to or unable to tolerate other tyrosine kinase inhibitors, and brigatinib, a lung cancer drug which has completed its registration trial in ALK fusion driven non-small cell lung cancer as of June 2016 and was approved in the U.S. in April 2017.

ARIAD raised $46 million as its initial financing in 1992, making it the single highest round of funding in the biotechnology industry at that time.

ARIAD is obligated to repay the $200 mm and a predefined interest, with the note being guaranteed by future sales of ponatinib[8] and in some cases, brigatinib.

ARIAD’s product pipeline includes brigatinib, an inhibitor of anaplastic lymphoma kinase [ALK] for treating ALK+ non-small cell lung cancer.

[23] Medinol has completed two registrational trials in patients with coronary artery disease, which met its primary and secondary endpoints.

[23][24] In October 2017, Medinol’s EluNIR drug eluting stent, coated with ridaforolimus, received CE Mark in Europe.

[27][28] AP32788 is a tyrosine kinase inhibitor of solid tumors with EGFR and HER2 activating mutation and began Phase 1/2 testing in the second quarter of 2016.